TXMD:NASDAQTherapeuticsMD, Inc. Analysis

TherapeuticsMD is trading at $1.82, which sits just above the computed support level of $1.80 and well below the DCF‑derived fair value of $4.41, suggesting a sizeable upside potential. The 20‑day SMA (2.02) is slightly above the current price, while the 200‑day SMA (1.80) provides a longer‑term floor, and the RSI of 29 signals that the stock is oversold. Technical momentum is bearish with a MACD histogram below zero and a bearish MACD signal, indicating short‑term downward pressure. Volume is increasing, offering some liquidity, but the 30‑day volatility of over 32% reflects a highly erratic price path. Fundamentally, the company posted a modest Q1 profit of $95 k and turned a net loss into a small profit year‑over‑year, yet operating margins remain negative and the PE ratio of 182 dwarfs the industry average of 25. The balance sheet shows ample cash ($8.4 M) versus debt ($4.8 M), giving a comfortable net cash position, while free cash flow is positive. No dividend is paid, and the company’s market cap is under $25 M, making it a micro‑cap with limited analyst coverage. Recent news confirms the earnings turnaround but also notes underperformance relative to peers, underscoring market skepticism. Overall, the stock appears undervalued on a DCF basis but carries high volatility, regulatory uncertainty, and thin liquidity that temper the upside.